MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Merck & Co Inc.

Closed

SectorHealthcare

79.89 1.46

Overview

Share price change

24h

Current

Min

76.03

Max

79.93

Key metrics

By Trading Economics

Income

583M

3.7B

Sales

-1B

16B

P/E

Sector Avg

11.55

57.333

EPS

1.72

Dividend yield

4.15

Profit margin

23.963

Employees

73,000

EBITDA

1.3B

6.9B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+36.76% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.15%

2.63%

Next Dividend date

7 lip 2025

Next Ex Dividend date

16 cze 2025

Market Stats

By TradingEconomics

Market Cap

-56B

196B

Previous open

78.43

Previous close

79.89

Technical Score

By Trading Central

Confidence

Neutral Evidence

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 kwi 2025, 18:18 UTC

Major Market Movers

Pharma Shares Reverse Losses After Tariff Pause

9 kwi 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 lut 2025, 12:33 UTC

Earnings

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 lut 2025, 11:57 UTC

Earnings

Merck 4Q Sales Increase Results in Swing to Profit

24 kwi 2025, 20:08 UTC

Earnings

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 kwi 2025, 16:05 UTC

Top News
Earnings

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 kwi 2025, 14:36 UTC

Market Talk
Earnings

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 kwi 2025, 14:10 UTC

Market Talk
Earnings

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 kwi 2025, 11:35 UTC

Earnings

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 kwi 2025, 10:58 UTC

Top News
Earnings

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 kwi 2025, 10:55 UTC

Earnings

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 kwi 2025, 10:31 UTC

Earnings

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Keytruda Sales $7.21B >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Keytruda Sales Up 4% >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 kwi 2025, 10:30 UTC

Earnings

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 kwi 2025, 09:13 UTC

Hot Stocks

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mar 2025, 05:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar 2025, 19:42 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar 2025, 10:30 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 lut 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 lut 2025, 14:48 UTC

Earnings

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 lut 2025, 11:51 UTC

Earnings

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 lut 2025, 11:50 UTC

Earnings

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 lut 2025, 11:31 UTC

Earnings

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 lut 2025, 11:31 UTC

Earnings

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 lut 2025, 11:31 UTC

Earnings

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

36.76% upside

12 Months Forecast

Average 108 USD  36.76%

High 138 USD

Low 85 USD

Based on 18 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

11

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

78.36 / 79.18Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.